Novel fully bioabsorbable salicylate-based sirolimus-eluting stent

EuroIntervention

Volumn 5, Issue SUPPL. F, 2009, Pages

  Jabara, Refat ^a,b   Pendyala, Lakshmana ^b   Geva, Sarah ^b   Chen, Jack ^b   Chronos, Nicolas ^b   Robinson, Keith ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Saint Joseph's Hospital of Atlanta   (United States)

Author keywords

Bioabsorbable stents; Salicylic acid; SES

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; RAPAMYCIN; SALICYLIC ACID;

ANGIOCARDIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; BIODEGRADABLE IMPLANT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; ELUTION; EQUIPMENT DESIGN; FOLLOW UP; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INTRAVASCULAR ULTRASOUND; MATERIAL COATING; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; POSTOPERATIVE INFLAMMATION; STENT THROMBOSIS; SWINE; TREATMENT OUTCOME;

EID: 79952061046     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/eijv5ifa10     Document Type: Article

References (21)

1. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202. (Pubitemid 43929240)
2. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR, Belknap SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L, Feldman MD. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175-181. (Pubitemid 43005183)
3. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007;27:1500-10. (Pubitemid 46986103)
4. Zidar J, Lincoff A, Stack R. Biodegradable stents. In: Topol EJ (ed) Textbook of interventional cardiology, 2nd edn. Saunders, Philadelphia, 1994;787-802.
5. Colombo A, Karvouni E. Biodegradable stents: "Fulfilling the mission and stepping away." Circulation 2000;102:371-373.
6. König A, Schiele TM, Rieber J, Theisen K, Mudra H, Klauss V Influence of stent design and deployment technique on neointima formation and vascular remodeling. Z Kardiol 2002;91(Suppl. 3):98-102. (Pubitemid 34809732)
7. Tsuji T, Tamai H, Igaki K, Kyo E, Kosuga K, Hata T, Nakamura T, Fujita S, Takeda S, Motohara S, Uehata H. Biodegradable stents as a platform to drug loading. Int J Cardiovasc Intervent 2003;5:13-16. (Pubitemid 36227310)
8. Yamawaki T, Shimokawa H, Kozai T, Miyata K, Higo T, Tanaka E, Egashira K, Shiraishi T, Tamai H, Igaki K, Takeshita A. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 1998;32:780-786. (Pubitemid 28435269)
9. Vogt F, Stein A, Rettemeier G, Krott N, Hoffmann R, vom Dahl J, Bosserhoff AK, Michaeli W, Hanrath P, Weber C, Blindt R. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 2004;25:1330-1340. (Pubitemid 38998510)
10. Hietala EM, Salminen US, Stahls A, Valimaa T, Maasilta P, Tormala P, Nieminen MS, Harjula AL. Biodegradation of the copolymeric polylactide stent: Long-term follow-up in a rabbit aorta model. J Vasc Res 2001;38:361-369. (Pubitemid 32678951)
11. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori H, Tsuji T, Motohara S, Uehata H. Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. Circulation 2000;102:399-404. (Pubitemid 30490677)
12. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr, Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690-1697. (Pubitemid 26320276)
13. Peuster M, Wohlsein P, Brugmann M, Ehlerding M, Seidler K, Fink C, Brauer H, Fischer A, Hausdorf G. A novel approach to temporary stenting: Degradable cardiovascular stents produced from corrodible metalresults 6-18 months after implantation into New Zealand white rabbits. Heart 2001;86:563-569. (Pubitemid 32999872)
14. Schmeltzer RC, Anastasiou TJ, Uhrich KE. Optimized Synthesis of Salicylate-based Poly( anhydride-esters). Polymer Bulletin 2003;49:441-448.
15. Erdmann L, Macedo B, Uhrich KE. Degradable poly(anhydride ester) implants: effects of localized salicylic acid release on bone. Biomaterials 2000;21:2507-2512.
16. Erdmann L, Uhrich KE. Synthesis and degradation characteristics of salicylic acid-derived poly(anhydride-esters). Biomaterials 2000;21:1941-1946. (Pubitemid 30433822)
17. Schmeltzer RC, Uhrich KE. Synthesis and Characterization of Salicylic Acid-Based Poly(Anhydride-Ester) Copolymers. Journal of Bioactive and Compatible Polymers 2006; 21:123-133. (Pubitemid 43260604)
18. Jabara R, Chronos N, Robinson K. Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating. Catheter Cardiovasc Interv 2008;72(2):186-194.
19. Schwartz RS, Edelman ER, Carter A, Chronos NAF, Rogers C, Robinson KA, Waksman R, Weinberger J, Wilensky RL, Jensen DN, Zuckerman BD, Virmani R. Drug-eluting stents in preclinical studies: Recommended evaluation from a consensus group. Circulation 2002;106:1867-1873.
20. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31:224-230. (Pubitemid 28064746)
21. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol 1992;19:267-274.